Page 15 - GPD-4-2

Gene & Protein in Disease Chinese herbs and stem cells in neurology

efficiency, minimize side effects, and pave the way for Diseases. Ch. 9. United States: Academic Press; 2017.
safer and more effective therapies. However, challenges p. 207-231.
remain, including potential immunogenicity, tumorigenic 4. Mokhtari T, Shayan M, Rashnudi AR, Hassanzadeh G,
risks, and dosage sensitivity for both stem cells and TCM Nia KM. Wharton’s jelly mesenchymal stem cells attenuate
ingredients. To harness these benefits and translate them global hypoxia-induced learning and memory impairment
into clinical practice, further research should focus on via preventing blood-brain barrier breakdown. Iran J Basic
refining combined therapy protocols, optimizing dosage Med Sci. 2023;26(9):1053.
and delivery methods, and conducting large-scale trials doi: 10.22038/IJBMS.2023.70137.15250
with rigorous safety and efficacy assessments. Future
studies should also establish clear patient selection criteria 5. Bonaventura G, Munafò A, Bellanca CM, et al. Stem cells:
Innovative therapeutic options for neurodegenerative
and evaluate long-term outcomes to ensure clinical diseases? Cells. 2021;10(8):1992.
applicability and improved patient care in the field of
neuroregenerative medicine. doi: 10.3390/cells10081992
6. Mehrannia K, Mokhtari T, Noori Mogehi SMH, et al.
Acknowledgments Intracerebroventricular injection of Wharton’ jelly
None. mesenchymal stem cells attenuates brain damage in rat
model of hypoxia: Optimization of vascular endothelial
Funding growth factor and downregulation of inflammatory factors.
J Contemp Med Sci. 2018;4(3): 134-139.
None.
7. Guo Y, Peng Y, Zeng H, Chen G. Progress in mesenchymal
Conflict of interest stem cell therapy for ischemic stroke. Stem Cells Int.
2021;2021:9923566.
The authors declare that they have no competing interests.
doi: 10.1155/2021/9923566
Author contributions 8. Burns TC, Quinones-Hinojosa A. Regenerative medicine
for neurological diseases-will regenerative neurosurgery
Conceptualization: Shima Mohammadi deliver? BMJ. 2021;373:n955.
Writing – original draft: Romina Kardan, Reyhaneh Ghotbi
Writing – review & editing: Shima Mohammadi doi: 10.1136/bmj.n955
9. Chiu AY, Rao MSJN. Cell-based therapy for neural
Ethics approval and consent to participate disorders-anticipating challenges. Neurotherapeutics.
Not applicable. 2011;8(4):744-752.
doi: 10.1007/s13311-011-0066-9
Consent for publication
10. Chan SF, Sances S, Brill LM, et al. ATM-dependent
Not applicable. phosphorylation of MEF2D promotes neuronal survival
after DNA damage. J Neursci. 2014;34(13):4640-4653.
Availability of data
doi: 10.1523/JNEUROSCI.2510-12.2014
Not applicable.
11. Surguchov A, Bernal L and Surguchev AA. Phytochemicals
References as regulators of genes involved in synucleinopathies.
Biomolecules. 2021;11(5):624.
1. Argueti-Ostrovsky S, Alfahel L, Kahn J, Israelson A. All
roads lead to Rome: Different molecular players converge doi: 10.3390/biom11050624
to common toxic pathways in neurodegeneration. Cells. 12. Gaur R. A brief history: Traditional Chinese medicinal
2021;10(9):2438. system. Pharmacol Res Mod Chin Med. 2024;10:100387.
doi: 10.3390/cells10092438 doi: 10.1016/j.prmcm.2024.100387
2. Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular 13. Mazzanti G, Di Giacomo S. Curcumin and resveratrol in
and cellular mechanisms underlying the pathogenesis of the management of cognitive disorders: What is the clinical
Alzheimer’s disease. Mol Neurodegener. 2020;15(1):40. evidence? Molecules. 2016;21(9):1243.
doi: 10.1186/s13024-020-00391-7 doi: 10.3390/molecules21091243
3. Chen KS, Feldman EL. Stem cell therapy for amyotrophic 14. Broman-Fulks JJ, Canu WH, Trout KL and Nieman DC. The
lateral sclerosis. In: Boulis N, O’Connor D, Donsante A, effects of quercetin supplementation on cognitive functioning
editors. Molecular and Cellular Therapies for Motor Neuron in a community sample: A randomized, placebo-controlled

Volume 4 Issue 2 (2025) 7 doi: 10.36922/gpd.4835